Hy-Vee Suspends Sale of Zantac Brand and Topcare Brand Ranitidine Products
September 30, 2019 | News & Press Releases
WEST DES MOINES, Iowa (Sept. 30, 2019) — Hy-Vee, Inc. has temporarily suspended the sale of all over-the-counter Zantac brand and Topcare brand ranitidine products. This action is being taken out of an abundance of caution due to a recent industry-wide product alert from the U.S. Food and Drug Administration (FDA) that ranitidine products may contain a low level of nitrosodimethylamine (NDMA), a probable human carcinogen.
The FDA is continuing to evaluate whether low levels of NDMA in ranitidine pose a risk to patients. The levels that the FDA is finding in ranitidine from preliminary tests “barely exceed amounts found in common foods.”
The FDA issued an official recall on Topcare 75mg ranitidine products, but no other Zantac brand products and Topcare brand ranitidine products have been recalled. Customers who purchased these products can return them to Hy-Vee for a full refund.
Ranitidine is an H2 Blocker that is taken to provide heartburn relief. Hy-Vee stores and Hy-Vee pharmacy locations will continue to sell other over-the-counter H2 Blockers, including Pepcid, Tagamet and their respective generic equivalents, famotidine and cimetidine.
Customers who have questions are encouraged to speak with their health care provider or their Hy-Vee pharmacist.
###
Hy-Vee, Inc. is an employee-owned corporation operating more than 260 retail stores across eight Midwestern states with sales of $10 billion annually. The supermarket chain is synonymous with quality, variety, convenience, healthy lifestyles, culinary expertise and superior customer service. Hy-Vee ranks in the Top 10 Most Trusted Brands and has been named one of America’s Top 5 favorite grocery stores. The company’s 80,000 employees provide “A Helpful Smile in Every Aisle” to customers every day. For additional information, visit www.hy-vee.com.